

Investigation Report on China Sodium Ibandronate Market, 2010-2019

https://marketpublishers.com/r/I1ACEA76A36EN.html

Date: June 2015

Pages: 30

Price: US\$ 2,000.00 (Single User License)

ID: I1ACEA76A36EN

Abstracts

Description

Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.

The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.

First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.

The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of



Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.

With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.

Readers can get at least the following information from this report:

market size of sodium ibandronate in China
competitive landscape of sodium ibandronate in Chinese market
price of sodium ibandronate made by different enterprises in China
market outlook of sodium ibandronate in China

The author suggests the following groups of people purchase this report:

manufacturers of anti-tumor drugs

investors/ research institutions interested in Chinese medicine market

any interest in the Chinese medicine market, please contact CRI for customized survey service



Contents

1 RELATED CONCEPTS OF SODIUM IBANDRONATE

- 1.1 Indication
- 1.2 Sales Status in Global Market

2 MARKET PROFILE OF SODIUM IBANDRONATE IN CHINA

- 2.1 Patent and Approval Status of Sodium Ibandronate in China
- 2.2 Major Manufacturers
- 2.3 Market Size

3 SURVEY ON SALES STATUS OF SODIUM IBANDRONATE IN CHINA, 2010-2014

- 3.1 Sales Value
 - 3.1.1 Overall Sales Value
 - 3.1.2 Sales Value by Regions
- 3.2 Sales Volume
 - 3.2.1 Overall Sales Volume
 - 3.2.2 Sales Volume by Regions

4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINA, 2010-2014

- 4.1 Market Share by Sales Value
- 4.2 Market Share by Sales Volume

5 SURVEY ON DOSAGE FORMS OF SODIUM IBANDRONATE IN CHINA, 2010-2014

- 5.1 Share of Different Dosage Forms by Sales Value
- 5.2 Share of Different Dosage Forms by Sales Volume

6 REFERENCE PRICE OF SODIUM IBANDRONATE IN CHINESE HOSPITALS IN 2014

- 6.1 Roche Diagnostics GmbH GE (Trade Name: BONVIVA)
- 6.2 Hencer Pharmacy (Trade Name: Jia Nuo Shun)
- 6.3 Easton Pharmaceutical Co., Ltd



6.4 Science & Technology General Company Hebei Medical University (Trade Name: Aiben)

7 MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINESE MARKET, 2010-2014

- 7.1 Hencer Pharmacy
- 7.2 Science & Technology General Company Hebei Medical University
- 7.3 Roche Diagnostics GmbH
- 7.4 Easton Pharmaceutical Co., Ltd

8 MARKET OUTLOOK OF SODIUM IBANDRONATE IN CHINA, 2015-2019

- 8.1 Forecast of Market Size
- 8.2 Forecast of Competitive Landscape

TABLE OF SELECTED CHARTS

Chart Approval Information of Sodium Ibandronate in China

Chart Sales Status of Sodium Ibandronate in China

Chart Sales Value of Sodium Ibandronate in China, 2010-2014

Chart Sales Value of Sodium Ibandronate in Some Regions in China, 2010-2014

Chart Sales Volume of Sodium Ibandronate in China, 2010-2014

Chart Market Share of TOP4 Manufacturers of Sodium Ibandronate for Sales Value in China, 2010-2014

Chart Sales Value and Market Share of Sodium Ibandronate Made by Science &

Technology General Company Hebei Medical University in China, 2010-2014

Chart Sales Value and Market Share of Sodium Ibandronate Made by Hencer

Pharmacy in China, 2010-2014

Chart Sales Value and Market Share of Sodium Ibandronate Made by Roche

Diagnostics(GE) in China, 2010-2014

Chart Sales Value and Market Share of Sodium Ibandronate Made by Easton in China, 2010-2014

Chart Price of Sodium Ibandronate Made by Roche Diagnostics GmbH GE in Some Chinese Cities in 2014

Chart Price of Sodium Ibandronate Made by Hencer Pharmacy in Some Chinese Cities in 2014

Chart Price of Sodium Ibandronate Made by Easton Pharmaceutical Co., Ltd in Some Chinese Cities in 2014



Chart Price of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in Some Chinese Cities in 2014



I would like to order

Product name: Investigation Report on China Sodium Ibandronate Market, 2010-2019

Product link: https://marketpublishers.com/r/l1ACEA76A36EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l1ACEA76A36EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970